Nanoparticle-induced chemoresistance: the emerging modulatory effects of engineered nanomaterials on human intestinal cancer cell redox metabolic adaptation

Nanoscale. 2022 Oct 13;14(39):14491-14507. doi: 10.1039/d2nr03893e.

Abstract

The widespread use of engineered nanomaterials (ENMs) in food products necessitates the understanding of their impact on the gastrointestinal tract (GIT). Herein, we screened several representative food-borne comparator ENMs (i.e. ZnO, SiO2 and TiO2 nanoparticles (NPs)) and report that human colon cancer cells can insidiously exploit ZnO NP-induced adaptive response to acquire resistance against several chemotherapeutic drugs. By employing a conditioning and challenge treatment regime, we demonstrate that repeated exposure to a non-toxic dose of ZnO NPs (20 μM) could dampen the efficacy of cisplatin, paclitaxel and doxorubicin by 10-50% in monolayer culture and 3D spheroids of human colon adenocarcinoma cells. Structure-activity relationship studies revealed a complex interplay between nanoparticle surface chemistry and cell type in determining the chemoresistance-inducing effect, with silica coated ZnO NPs having a negligible influence on the anticancer treatment. Mechanistically, we showed that the pro-survival paracrine signaling was potentiated and propagated by a subset of ZnO NP "stressed" (Zn2++/ROS+) cells to the surrounding "bystander" (Zn2++/ROS-) cells. Transcriptome profiling, bioinformatics analysis and siRNA gene knockdown experiments revealed the nuclear factor erythroid 2-related factor 2 (Nrf2) as the key modulator of the ZnO NP-induced drug resistance. Our findings suggest that a ROS-inducing ENM can emerge as a nano-stressor, capable of regulating the chemosensitivity of colon cancer cells.

MeSH terms

  • Adenocarcinoma*
  • Cisplatin
  • Colonic Neoplasms* / drug therapy
  • Doxorubicin / pharmacology
  • Drug Resistance, Neoplasm
  • Humans
  • NF-E2-Related Factor 2 / metabolism
  • Nanoparticles* / toxicity
  • Nanostructures*
  • Oxidation-Reduction
  • Paclitaxel / pharmacology
  • RNA, Small Interfering / metabolism
  • Reactive Oxygen Species / metabolism
  • Silicon Dioxide / pharmacology
  • Zinc Oxide* / pharmacology

Substances

  • NF-E2-Related Factor 2
  • RNA, Small Interfering
  • Reactive Oxygen Species
  • Silicon Dioxide
  • Doxorubicin
  • Paclitaxel
  • Cisplatin
  • Zinc Oxide